A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (NCT06206837)
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology โ Fayetteville, Arkansas
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (58 Sites)
Showing the first 25 of 58 sites.
- Highlands Oncology โ Fayetteville, Arkansas
- Highlands Oncology โ Rogers, Arkansas
- Highlands Oncology Group โ Springdale, Arkansas
- Hoag Health Center Irvine โ Irvine, California
- Hoag Hospital Irvine โ Irvine, California
- Hoag Memorial Hospital Presbyterian โ Newport Beach, California
- Stanford Cancer Center โ Palo Alto, California
- Stanford Cancer Institute - Clinical Trials Office โ Palo Alto, California
- Stanford Women's Cancer Center โ Palo Alto, California
- UCSF Medical Center at Mission Bay โ San Francisco, California
- UCHealth Poudre Valley Hospital โ Fort Collins, Colorado
- UCHealth Harmony โ Fort Collins, Colorado
- UCHealth Greeley Hospital โ Greeley, Colorado
- UCHealth - Medical Center of the Rockies โ Loveland, Colorado
- Smilow Cancer Hospital - Yale New Haven Health โ New Haven, Connecticut
- Yale - New Haven Hospital - Yale Cancer Center โ New Haven, Connecticut
- Smilow Cancer Hospital Phase 1 Unit โ New Haven, Connecticut
- Smilow Cancer Hospital - Trumbull โ Trumbull, Connecticut
- START Midwest โ Grand Rapids, Michigan
- MSK Basking Ridge โ Basking Ridge, New Jersey
- MSK Monmouth โ Middletown, New Jersey
- MSK Bergen โ Montvale, New Jersey
- MSK Commack โ Commack, New York
- MSK Westchester โ Harrison, New York
- Rockefeller Outpatient Pavilion (53rd Street) โ New York, New York
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer โ Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer โ Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery โ Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) โ Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer โ Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer โ Duarte, California
Explore by condition: All Breast Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.